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Recent studies have shown that the potent phosphodiesterase-5 (PDE-5) inhibitor, 
sildenafil citrate, induces a powerful cardioprotective effect against ischemia-reperfusion 
(IIR) injury in rabbit and mouse hearts. However, the effect of this drug in inducing long- 
term protection against VR injury remains unknown. The goal of this study was to identify 
the duration of the protective window of sildenafil citrate as well as vardenafil, a more 
potent PDE-5 inhibitor. Rabbits were treated with sildenafil (0.7 mg/kg, iv), vardenafil 
(0.143 mglkg), or an equivalent volume of saline. After 24 hrs, 48 hrs, 96 hrs, or 7 days of 
vii 
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sildenafil treatment, the hearts were subjected to I/R. In the vardenafil groups, the hearts 
were subjected to I/R at 24 hrs and 7 days after administration of the drug. To evaluate the 
role of nitric oxide (NO) in cardioprotection, a non-selective blocker of nitric oxide 
synthase, L-NAME (1 5 mgkg, iv) was administered 10 minutes prior to IIR. The results 
show significant reductions in infarct size in hearts treated with sildenafil and vardenafil as 
compared to the corresponding saline controls at all time points. The protective effects of 
sildenafil and vardenafil were abrogated in animals treated with L-NAME. L-NAME had 
no effect on infarct size in saline treated control rabbits. These data suggest that both 
sildenafil and vardenafil induce a long-term protective effect against myocardial infarction 
which is mediated via a NO-dependent pathway. These studies are important in exploiting 
the clinical potential of PDE-5 inhibitors in terms of protection against 
ischemia~reperfbsion injury in patients with coronary artery disease. 
INTRODUCTION 
Restoration of blood flow (reperfusion) to a previously ischemic organ or tissue is a 
necessary step in the recovery process; however, there is a caveat. Reperfusion can further 
propagate an injury and ultimately result in myocardial cell death. A reduction in the 
amount of viable myocardium leads to an inevitable decrease in the ability of the heart to 
perform its primary function: the pumping of blood to both the systemic and pulmonary 
circuits. Clearly, preserving any myocardial tissue after an ischemic insult is beneficial in 
the clinical realm. Such implications could have profound effects on the lives of many 
individuals who suffer from the various cardiovascular problems in our present time. 
Ischemic preconditioning is a cardioprotective mechanism against myocardial-cell 
death and cardiac dysfunction that results from the reperfusion of an ischemic heart (29). 
Murry et a1 used brief periods of ischemia to evaluate a potential preconditioning effect in 
the canine heart (26). These authors demonstrated that a brief episode of ischemia slowed 
the rate of ATP depletion that occurs during subsequent ischemic episodes. It was also 
shown that periods of intermittent reperfusion may be beneficial to the myocardium in that 
they washed out catabolites that tend to accumulate during an ischemic event. They found 
that ischemic preconditioning resulted in a significant reduction of infarct size within the 
at-risk area of the canine heart by an average of 25% when compared to controls (26). 
Studies in both the rabbit and the canine heart have demonstrated that the 
cardioprotective effect of ischemic preconditioning appears in two phases: an acute or 
classical phase which is detectable within minutes after bI;ief episode(s) of ischemia and 
reperfusion and the delayed phase, which appears 24 hours following the initial ischemic 
insult and has been shown to last up to 96 hrs (2 1, 24). Classical forms of preconditioning 
have limited significance in the clinical realm due to the narrow time window within which 
the myocardium is actually protected. However, delayed preconditioning is relevant 
clinically in that it follows approximately 24 hours after the insult and tends to last much 
longer than classical preconditioning. The delayed phase of preconditioning can be 
produced not only via sub-lethal ischemia, but also by heat shock (10) and various other 
endogenously released triggers such as adenosine (3), norepinephrine (2), bradykinin (20), 
oxygen radicals (7) and opioids (35). It has been widely accepted that the delayed 
cardioprotective window induced by said pharmacological agents is mediated by an 
increase in NO production (4, 45). Moreover, NO may modulate KATp-channel sensitivity 
to intracellular ATP (38). Several studies have shown the importance of mitochondrial 
KATP channels in cardioprotection (8). Using diazoxide, a mitochondrial KATP channel 
opener, Garlid et a1 were able to produce significant cardioprotective effects in an isolated, 
perhsed heart (14). Furthermore, Liu et a1 found a substantial reduction in the rate of cell 
death following simulated ischemia in adult ventricular myocytes (23). The protection 
provided by the mitochondrial KATP channels was confirmed when the cardioprotective 
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effects were abolished upon the addition of 5-hydroxydecanoate (5-HD), a selective 
mitochondria1 KATP channel blocker (23). 
It is clear from the brief review above that extensive research and publications in 
the field of ischemic preconditioning have vastly extenged our understanding of the 
mechanisms underlying the pathogenesis of I/R injury. There can be little doubt that the 
elucidation of the pathophysiology and cellular mechanisms of the phenomenon of 
ischemic preconditioning have enabled us to learn a means of protecting the myocardium 
in the experimental setting. This evolving field, however, has so far failed to provide any 
direct evidence that this plethora of experimental and clinical research may one day 
translate into a clinical reality that would ultimately benefit patients with coronary artery 
disease. Despite this, the knowledge gained as a result of this research has provided us 
with tools for protecting myocytes and has enabled us to identify several classes of 
pharmacological agents that may be able to mimic the protection conferred by ischemic 
preconditioning. These include agents aimed at triggering the preconditioning 
phenomenon such as adenosine or its more selective analogues, bradykininlangiotensin- 
converting enzyme inhibitors and opioids, and those that target the putative distal mediator 
of preconditioning (mito-KATP channels), such as nicorandil. 
In the quest for novel drugs in preconditioning, Dr. Kukreja and colleagues used 
phosphodiesterase-5 (PDE-5) enzyme inhibitors for cardioprotection. PDE-5 inhibitors are 
the class of drugs used for the treatment of erectile dysfunction (ED) in men. Sildenafil 
citrate (viagram) is one such drug approved for ED (5, 18). It has a proven record of safety 
in humans as predicted by the results of extensive pharmacological and toxicological 
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testing in animals and in vitro. This has been confirmed by pharmacokinetic exposure data 
as well (1). Sildenafil selectively inhibits PDE-5, the enzyme that catalyzes the breakdown 
of cyclic-GMP, a potent, endogenous, smooth muscle relaxant. Sildenafil acts by 
competing with cGMP for the active site on PDE-5 (9). Stydies have shown that sildenafil 
also serves to enhance nitric oxide (NO)-driven cGMP accumulation in the corpus 
cavernosum of rabbits without affecting the formation of cyclic-AMP. In the absence of a 
NO drive, sildenafil potentiated the relaxing effects of NO in the isolated corpus 
cavernosum, but had no functional effect on said tissues isolated from both the human and 
the rabbit (32). Many of the biological actions of NO occur via the activation of soluble 
guanylyl cyclase (GC) and the resulting increase in cGMP tissue levels. Moreover, cGMP 
has been shown to exert a number of actions that would be expected to be beneficial during 
myocardial ischemia (44, 22, and 37). According to studies by Kodani et al, the increased 
synthesis of cGMP is necessary in order to produce cardioprotection in delayed ischemic 
PC in the rabbit heart (1 9). 
Vardenafil is the active ingredient in another PDE-5 inhibiting drug for ED called 
~ e v i t r a ~ .  Like sildenafil, vardenafil binds to the active site on the PDE-5 enzyme, thereby 
inhibiting the binding of cGMP and thus preventing the breakdown of cGMP (9). For 
cardioprotection studies, it was hypothesized that the mild vasodilatory effect of sildenafil 
could potentially release agents such as adenosine, bradykinin, or nitric oxide, which may 
in turn trigger a preconditioning-like effect in the myocardium (28). Studies have shown 
that, in the rabbit heart, sildenafil induced both acute and delayed cardioprotective effects, 
both of which were occurring through a pathway dependent on the opening of 
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mitochondrial KATP channels (28). Salloum et a1 have further demonstrated that sildenafil 
causes an increase in endothelial (eNOS) and inducible NO synthase (iNOS) in the mouse 
heart and that the magnitude of increase was more pronounced for iNOS than for eNOS 
(32). A direct protective effect of sildenafil was also shown against necrosis and apoptosis 
in cardiomyocytes through a NO-signaling pathway (1 1). Furthermore, Das et a1 found 
that sildenafil enhanced mRNA and protein content of both iNOS and eNOS. In the same 
study, myocytes treated with sildenafil prior to simulated ischemia and reoxygenation 
showed a significant increase in the anti-apoptotic protein, Bcl-2. The increased 
expression of Bcl-2 was inhibited by L-NAME, an inhibitor of nitric-oxide synthases. It 
was also suggested that sildenafil may trigger a signaling cascade that involves the 
generation of NO and the accumulation of cGMP in the myocytes through an eNOS- and 
iNOS-dependent pathway. This would therefore lead to the opening of the mitochondrial 
KATP channels and thus allow for the observed cardioprotective effects (1 1). 
Goals of the Study 
Although previous studies from our laboratory have shown the protective effect of 
sildenafil against IIR injury up to 24 hrs after treatment, it is unclear whether sildenafil or 
vardenafil have a long lasting protective effect extending beyond the 24-hour period. The 
current study was designed to identify the window of cardioprotection induced by these 
drugs in vivo. Since NO was observed to be an essential component of delayed protection 
at 24 hrs with sildenafil (32), we were interested in further identifying the role of NO in 
long-term protection with PDE-5 inhibitors. Accordingly, we addressed the following two 
questions in the present study: 
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1. To determine the time course of the cardioprotective effect of sildenafil 
and vardenafil in the rabbit model of ischemiah-eperfusion injury. 
2. To show the role of NO in inducing a cardioprotective effect during 
long-term protection with sildenafil and vqrdenafil. 
Our results show that both drugs reduced infarct size following I/R injury, which 
was observed up to 7 days and possibly even longer after the treatment. Moreover, the 
non-selective nitric oxide synthase inhibitor, L-NAME (N,-Nitro-L-arginine methyl ester 
hydrochloride), blocked the protective effect, thus confirming the role of a NO-dependent 
pathway. 
MATERIALS AND METHODS 
Animals 
Male New Zealand White rabbits, obtained from Blue and Gray Rabbitry 
(Unionville Lane, Virginia), were used in this study. The rabbits were weighed (2.5 kg to 
3.5 kg) and the values were recorded directly on the animals' ear for proper identification. 
The care and use of the animals were conducted in accordance with the guidelines of the 
Institutional Animal Care and Use Committee of Virginia Commonwealth University and 
the National Institutes of Health (NIH) Guides for Care and Use of Laboratory Animals 
[DHHS Publication No. (NIH) 80-23; Office of Science and Health Reports, Bethesda, 
MD 202051. Each group was comprised of 6 animals. 
Drug Preparation and Administration 
Sildenafil citrate (viagraB) tablets were crushed and ground to a fine powder using 
a ceramic mortar and pestle. The compound was then weighed and dissolved in 3 cc of 
sterile 0.9% saline solution (0.7 mgkg sildenafil citrate). The drug was administered 
intravenously through left or right ear via the marginal vein. Depending on the 
experimental group, the rabbits were allowed to remain for 24, 48, 96, or 168 hours (7 
days) prior to undergoing the surgery protocol as described below. L-NAME (15 mgkg) 
was given to the appropriate groups intravenously 10 minutes before ischemia. A pure 
compound of vardenafil HC1 was weighed, with 1 mg of the compound being dissolved in 
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7 ml of 0.9% saline. Each animal received 0.143 mgkg of vardenafil. The drug was given 
intravenously through the marginal vein in the ear. 
Surgical Procedure 
The rabbits were given a 1.5 cc injection (intramuscularly) that contained ketamine 
HCl(35 mgkg), xylazine (5 mglkg), and atropine. The atropine was administered in order 
to sustain an elevated heart rate throughout the entire surgical protocol. Subsequent doses 
of anesthetic were given at 40 minute intervals in order to maintain appropriate levels of 
surgical anesthesia. 
A ventral midline incision was made in the neck. A tracheotomy was performed, 
followed by intubation of the animal. The animals were ventilated mechanically with a 
positive-pressure ventilator and oxygen was administered via the ventilator as well. The 
left carotid artery was dissected and cannulated with a polyethylene (PE) catheter and 
filled with saline and heparin for continuous arterial pressure and hemodynamic 
monitoring. The right jugular vein was also cannulated with a PE catheter containing 
saline with heparin for continuous infusion of 0.9% saline solution. In some cases, 
electrocardiographic leads were attached to subcutaneous electrodes in order to monitor 
either limb lead I1 or lead 111. Baseline values for systolic and diastolic blood pressure 
were recorded, as well as values for mean arterial pressure and heart rate. 
After hemodynamic stabilization was achieved, a left thoracotomy was performed 
via the fourth intercostal space. The pericardium was then opened in order to gain access 
to the heart. Hemodynamic data were recorded again after the thoracotomy and just prior 
to the induction of ischemia. A 5-0 silk suture equipped with an atraumatic needle was 
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used to circumvent the left anterior descending (LAD) coronary artery at the halfway point 
between the atrio-ventricular groove and the apex of the heart. The needle was cut from 
the suture and the two ends were passed through a vinyl tube that had previously been 
heated and slightly melted so as to not cause damage to the, myocardial tissue and to form 
an effective snare. The smooth end of the snare was pressed securely against the heart and 
fixed in place with a hemostat in order to occlude the vessel (Figure 1). Ischemia in the 
myocardium was confirmed either by direct visualization of the tissue in situ due to the 
presence of regional cyanosis, ST elevation and subsequent depression on the 
electrocardiogram, or T wave inversion on the electrocardiogram. After 30 minutes of 
ischemia, blood pressure and heart rate values were recorded, and the snare was released. 
The suture remained in place although it was no longer preventing blood flow within the 
LAD. The area was gently massaged with a cotton-tipped applicator to promote regional 
blood flow. Reperfusion of the heart was allowed to occur for 180 minutes. Reperfusion 
was confirmed by hyperemia in the regions of the myocardium that were previously 
cyanotic. Pressure and heart rate measurements were taken every 60 minutes during the 
reperfusion phase of the protocol. To prevent desiccation, the thoracic cavity was covered 
with a piece of saline-soaked gauze. 
Upon completion of the VR protocol, the heart was removed and mounted on a 
Langendorff apparatus. The coronary arteries were perfused with a 0.9% saline solution 
containing 2.5 mM CaC12 in order to wash out any blood that remained. The suture around 
the LAD was tied off completely and about 2 ml of 10% Evan's blue dye were injected 
into the aorta until most of the heart turned blue. The excess Evan's blue dye was washed 
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away by perfusing the heart with more saline. The heart was then removed from the 
Langendorff apparatus, placed into a Petri dish, and moved to a freezer for approximately 
24 hours to facilitate the next step in the protocol. The frozen heart was then cut into 
approximately 6 transverse slices of equal thickness, startiqg from the apex and ending at 
the base. The slices were then incubated in 1% 2,3,5-triphenyltetrazolium chloride (TTC) 
solution of isotonic pH 7.4 phosphate buffer at 37OC for 20 minutes. The TTC reacts with 
NADH in the presence of dehydrogenase enzymes, causing the viable cells to stain with a 
deep red color and the dead myocardial tissue to remain pale in color. This allowed for 
easy differentiation between viable tissue and infracted gray or white necrotic tissue. 
Following the staining with TTC, the slices were fixed with a 10% formalin solution. The 
at-risk area was determined using negative staining with the Evan's blue dye. The portions 
of tissue that were not at risk from coronary occlusion stained a deep blue color while the 
at-risk regions did not. Computer morphometry (Bioquant imaging software - BI098) was 
used to measure the area of infracted tissue, the risk zone, and the whole left ventricle. 
Infarct size has been expressed as a percentage of the ischemic risk area. 
Statistical Analysis 
All measurements of infarct size and risk areas are expressed as group means * 
SEM. Changes in hemodynamics and infarct size variables were analyzed by two-way 
repeated-measures ANOVA to determine the main effect of time, group, and time-by- 
group interaction. If the global tests showed major interactions, post hoc contrasts between 
different time points within the same group or between different groups were performed 
using a t-test. Statistical differences were considered significant if the P value was <0.05. 
Figure 1. Snare placement and infarction. After the left thoracotomy was performed, 
the LAD was identified and a 5-0 silk suture passed around it. The two ends of the thread 
were passed through the tubing and the snare was fixed in place via a hemostat. 
Confirmation of successful occlusion was achieved by noting regional cyanosis, as seen in 
this photograph. 
RESULTS 
Risk Area and Infarct Size 
The risk areas for all of the hearts were similar in size, ranging from 46.20% + 3.48 
to 58.05% f 6.78 (Figures 2, 4 and 6). These data suggest that changes in the infarct size 
observed among various groups were not related to the percentage of the area of the left 
ventricle that was occluded by our technique. In figure 3, it is clear that the group with the 
smallest infarct size (% of risk area) was the one receiving sildenafil from 48-168 hrs prior 
to VR. Overall, it can easily be seen that the groups receiving sildenafil, regardless of the 
time interval, had much smaller infarcts when compared to the control groups (Figure 3). 
As seen in figure 5, the addition of L-NAME abolished the protection conferred by 
sildenafil. The animals receiving sildenafil 24 hrs prior to VR had an average infarct size 
of 19.77% f 1.46, which was increased to 30.77% + 1.83 in L-NAME treated rabbits. 
Such increase in the infarct size in sildenafil + L-NAME treated animals was not different 
when compared with saline treated controls (35.89% + 1.54). Similarly, the group of 
animals receiving sildenafil 168 hrs prior to I/R had an infarct size of 16.37% + 1.94 which 
increased to 3 1.61% f 1.22 following treatment with L-NAME. Again this increase in 
infarct size was not significantly different as compared to the saline treated control 
animals, which had an average infarct size of 37.28% + 1.39 (Figure 5). L-NAME alone 
13 
had an infarct size of 34.9 % f 0.91, which was not significantly different when compared 
to the saline treated control groups 35.89 % f 1.54 (24 hrs) or 37.28 % f 1.39 (168 hrs) 
subjected to ischemia/reperhsion protocol. 
In figure 7, the groups receiving vardenafil showed, significant protection at 24 hr 
and 168 hr (7 days) time intervals. The infarct size was 18.3 1 f 1.73 and 22.09 f 1.12 in 
the vardenafil-treated rabbits, which was significantly lower as compared to the infarct 
sizes of 33.4% f 1.03 and 34.8% k 1.61 in the saline treated controls at 24 and 169 hrs 
respectively. Similar to sildenafil, treatment with L-NAME abolished the ~ardio~rotective 
effect of vardenafil. The infarct size increased to 32.31% f 2.24 at 24 hrs and 31.24% f 
1.51 at 168 hrs following treatment with L-NAME. The infarct sizes in vardenafil + L- 
NAME treated groups were comparable to the saline-treated controls: 33.4% f 1.03 and 
34.8% f 1.6 1 at 24 and 168 hrs after treatment, respectively (Figure 7). 
Hemodynamic Findings 
The changes in hemodynamics immediately following treatment with sildenafil and 
vardenafil have been reported previously from the laboratory (28, 31). Intravenous 
administration of sildenafil citrate induced a rapid decrease in the hemodynamics as 
demonstrated by the 24.5%, 47.3%, and 38.8% decline in systolic, diastolic, and mean 
arterial pressures, respectively, within 2 min. The systemic hemodynamics bounced back 
to nearly baseline levels within 5 min after treatment with sildenafil. No significant 
changes in heart rate were observed. Similarly, after treatment with vardenafil, the mean 
arterial blood pressure decreased from 93.5 h 2.6 to 82.2 1.5 mm Hg and heart rate 
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(beatslminute) increased from a baseline value of 151 * 20 to 196 * 4.6 (mean * SEM, 
p<0.05) within 5 minutes of drug administration. 
During IIR, the heart rate, MAP and RPP are shown in Table 1 (for sildenafil and 
controls), Table 2 (for sildenafil + L-NAME) and Table 3 (for vardenafil and vardenafil + 
L-NAME). There was no significant difference in the baseline levels of these parameters 
between the different groups. Moreover, the heart rate, MAP and RPP remained 
reasonably stable throughout the reperfusion period, though there was a gradual decrease 
in all of the groups during this time. Except at the indicated time points, the mean values 
were not significantly different between the groups at any time point. Significant 
decreases in heart rate were observed in the groups treated with L-NAME. Also, the rate- 
pressure product was found to be significantly lower in the L-NAME treated groups as 
compared to the other groups during IIR. 
U Sildenafil 24hrs 
Control 24hrs 
Sildenafil48hr.s 
Control 48hrs 
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Figure 2. Risk area for long-term sildenafil treatments and controls. The risk area of 
the left ventricle was determined using Evan's blue dye. 
0 Sildenafil 24hrs 
Control 24hrs 
ISildenafil 48hrs 
Control 48hrs 
E Sildenafil 96hrs 
Control 96hrs 
Sildenafil 168hrs 
tZA Control 168hrs 
Figure 3. Infarct size of long-term sildenafil treatments and controls. TTC staining 
was used to assess the amount of viable tissue remaining in the myocardium. Infarct size 
is expressed as a percentage of the at-risk tissue that suffered from infarction. Control 
groups received saline only. 
0 Sildenafil 24hrs 
Control 24hrs 
Sil + LNAME 24hrs 
Sildenafil 168hrs 
E Control 168hrs 
Sil + LNAME 168hrs 
Figure 4. Risk area for sildenafil treatments and L-NAME. The L-NAME, a NO- 
synthase inhibitor, was given 10 minutes prior to ischemia. Evan's blue dye was used to 
determine the at-risk area of the left ventricle. 
0 Sildenafil 24hrs 
Control 24hrs 
Sil + LNAME 24hrs 
Sildenafil 168hrs 
E Control 168hrs 
Sil + LNAME 168hrs 
Figure 5. Infarct size of sildenafil treatments and L-NAME. L-NAME was given 10 
minutes prior to ischemia-reperfusion. TTC staining was used to assess the amount of 
viable tissue present within the risk area. 

Table 2: Hemodynamic data for sildenafil groups and saline controls 
Group I Baseline I Pre-Ischemia I 30-min Ischemia 1 60-min 
1 Reperfusion ( Reperfusion I Reperfusion 
Sil24 hrs (Group I) 
MAP 1 8 5 f 5  1 8 3 f 2  1 7 2 f 4  1 6 9 f 5 "  1 6 ~ + 4 ~ . '  1 62f4e9f 
HR 
MAP 
RPP 
Saline Control 24 hrs (GrouplI) 
HR 
MAP 
RPP 
182f 15 
8 4 f 2  
17709f2217 
RPP 1 15528f1500 ( 16852k2046 1 15821f1425 1 13345f1952 1 12859f2121 1 11178f1864 
Saline Control 48 hrs (Group IV) 
187f 9 
100 f 7" 
10482 f 1 762a3b.c 
MAP 
RPP 
Sil96 hrs (Group V) 
HR 
MAP 
"P<O.05 vs Sil7 days, b ~ < ~ . 0 5  vs Sil24hrs, 'P<O.05 vs Sil96hrs, d ~ < ~ . 0 5  vs Sil48hrs, 'P<O.05 vs baseline,'p<0.05 vspre-ischemia, g ~ < 0 3 5  vi 30 
min ischemia. 
190f 14 
80 f 2" 
17248f 1708 
Sil48 hrs (Group 111) 
HR 
- 
RPP 1 16566f2253 ( 16759f1345 ( 14122f1109 1 11464f1042 1 11628f1603 ( 11040f1535 
Saline Control 96 hrs (Group VI) 
205 f 11 206f  12 
98 f 8" 
10260 f 1 872a.b-c 
HR 
MAP 
RPP 
Sil7 days (Group VII) 
HR 
MAP 
RPP 
Saline Control 7 days (Group VIII) 
HR 
MAP 
RPP 
169 f 6 
66 f 3eqf 
12937 f 8 ~ 7 ~ * '  
191 f 14 
96 f 6' 
967 1 f 1 1 2 8 % ~ ~ ~  
HR 
177f 12 
79 f 3 " ~ " ~  
6545 f 495a3c3de 
182f  13 
80 f 3 bs.e 
6669 + 469"C.de 
189f 8 177f 11 
185f 13 
95 f 5"' 
9503 f 1 0 1 5 " ~ ~ ~  
Values are means * SEM. HR - Heart rate (beatdmin); MAP - Mean arterial blood pressure (mmHg); RPP - Rate pressure product (mmHg/min), 
181 f 7  
9 7 f  4 
9680 f 722a,b.c 
198f 15 
7 5 f  5 
17180f1043 
199f 13 
9 4 f  5 
9458 f 922aqb-c 
143f 10' 
64 f 3e-f 
10575 f 732"' 
168f 13 
75 f 3".' 
591 8 f 526"C.de-f 
187f 7 
1 9 3 f 1 l " ~  ( 1 9 0 f 1 2 ~  
83 f 4a,b-c 
7161 f 752a.C3d 
163f 18 
8 5 f 3  
187f 9 
94 f 4a" 
9222 f 863a.b,d 
201 f 14 
74 f 5 
17265f1038 
201 f 7 
9 3 f  4 
9054 f 687"b.d 
126 f 1 2 ~ ~ '  
66 f se3' 
9 1 10 f 976",' 
164f 15 
70 f 6e9f 
5208 f 736ac.4e.f 
190f 1 2 ~  
195f 7 
59 f 4e-f 
1 8 6 f 9  
7 7 f  3 
135 f 13~.' 
61 f se.' 
9639 f I O O ~ ~ . '  
158f 11 
78 f 4' 
6380 f 660%"~ 
1 8 8 f 8  
78 f 2e3f 
6342 f 364a9c.4e.f 
1 9 7 f 8  
65 f 3 
15905 f 1 132 
196 f 7 
82 f 4a.b,C 
6959 f 709a9c.de.f 
168f 10 
55 f 3e2f 
l 5 8 f  14 
73 f 5".' 
5678 f 823a.c34e 
181 f 9 
75 f Fe.' 
5868 f 378"c9de.f 
148 f 
6 9 + 4  
12044 f 858e3f9g 
193 f 6ab 
73 f 3e.f 
5579 f 5 16a.c3de.f 
15Of 15 
71 f 6e*f 
5217 f 8 1 6 " ~ ~ ~ ~  
159 f 14 
59 f 6".' 
154 f 14 
58 + 6e.f 
174f 11 
71 f 2".' 
5277 + 2 1 2 " ~ ~ ~ ~ "  
145 f 8e,f*g 
69 f 2 
1 1 5 1 3 f 647e,f,g 
196 f 6"b 
69 f 4e.f 
5037 f 6194C-de3f 
170f 13 
64 f 4e3f 
4362 f 4 0 9 ~ ~ . ~ " . '  
14 1 f 6e3f3g 
6 6 f  3 
1 0773 f 807"~'~~ 
196f 7"b 
64 f 4e.f 
4365 f 542ac9de9f 
Table 3: Hemodynamic data for 
Group 
Sil24 hrs (Group I) 
HR 
MAP 
W P  
Saline Control 24 hrs (Group 11) 
HR 
MAP 
RPP 
Sil24 hrs + L-NAME (Group 111) 
H R 
MAP 
RPP 
Sil 7 days (Group IV) 
HR 
MAP 
RPP 
Saline Control 7 days (Group V) 
HK 
MAP 
RPP 
Sil7 days + L-NAME (Group VI) 
HR 
MAP 
RPP 
L-NAME Control (Group VII) 
HK 
MAP 
RPP 
Values are means * SEM. HR - Heart 
"P<0.05 vs Sil24hrs, b~<0 .05  vs saline 24hrs, 'P<0.05 vs saline 7 days, d~<0.05  vs baseline, 'P<0.05 vs pre-ischemia, f ~<0 .05  vs 30min ischemia. 
and controls 
30-min Ischemia 
169f 6 
66 + 3d.e 
12937+887d.e 
l77+ 12 
79 f 3a.d 
6545 f 49sd 
135 + I lb,' 
84 f 5" 
13124f 1376"' 
197f 8 
65 f 3b.C 
15905 f 1 1 3 2 ~ ~ '  
sildenafil, sildenafil 
Baseline 
182f 15 
8 4 f  2 
17709f2217 
1 8 7 f 9  
100f 7 
10482f1762" 
169f 20' 
84 + 8 
15938 f 1138 
198 f 15 
75 + 5b 
171 80 f 1043~.' 
199+ 13 
9 4 + 5  
9458 f 922" 
182f 13 
8 4 + 4  
17508 f 1453~.' 
182 + 8 
8 5 f  6 
17837 + 920b.' 
rate (beatdmin); 
+ L-NAME 
Pre-Ischemia 
190f 14 
80 f 2 
17248f1708 
191 f 14 
9 6 f 6  
9671f1128" 
144f 16 
107+ 14 
15488 +2421 
201 f 14 
7 4 + 5  
17265 f 1038~~' 
201 + 7 
93 + 4  
9054 f 687" 
158f 1 1  
91 f 3 
171 88 f 1 264b.' 
191 f 9 
101 f 23 
17426 f 805"' 
MAP - Mean 
60-min 
Reperfusion 
143 + 10" 
64 + 3d,e 
10575 + 732'" 
182+ 13 
8 0 f  3ad 
6669 f 469d 
130 + 8b.C 
87 f 3".' 
12474 f 907~,' 
148 f I o'.'",~ 
6 9 + 4  
12044 + 858b.c.4e.f 
196f 7ab 
64 + 4d.e.f 
4365 + 542d," 
1 18 f 8',d 
7 4 + 7  
9802 f 293b,c,de,f 
138f 15' 
6 8 f  1 
1076 1 f 999b.c.de 
(mmHg/min). 
120-min 
Reperfusion 
126 f 1 2d,e 
66 f sd," 
91 10 f 976d," 
168f 13 
75 f 3d,e 
59 18 + 526d,e 
128f 10' 
7 9 f  3 
1 127 1 f 700b.' 
145 f 8C,d,e,f 
6 9 + 2  
1 15 13 f 647b3'.d".f 
196f 7 
82 f 4" 
6959 f 709~," 
180-min 
Reperfusion 
135 f 13d.e 
61 +5d,e 
9639 f 1 0 0 3 ~ ~  
164 f 15 
70 f 6d.e 
5208 f 736d.e 
119f 9' 
76 + 3 
1001 5 + 524b.c,d 
14 1 + 6c,d.e3f 
6 6 + 3  
10773 + 807~,','",~ 
193 f 6" 
73 f 3d,e 
5579 + 516d.e 
196+6" 
69 f 4'" 
5037 f 619d.e 
145 + 1 
82 f 4" 
14022 + 1 126"',~," 
129 + 8b.c.d 
86 f 3a.d 
12390 f 690~.' .~" 
129 + 
77 f 6 
1 1859 f 506~,' .~" 
177f 13 
7 5 f  3 
14346 f 103Sb.' 
arterial blood pressure (mmHg); RPP - Rate pressure product 
160f 19 
70+ 1 
12609 f 1 1 84b,c,d.e 
155 f 20' 
6 9 2  1 
12286 f 1 397b.c.d.e 
Table 4: Hemodynamic data for vardenafil, vardenafil + L-NAME and controls 
Gram I Baseline I Pre-Ischemia 1 30-min Ischemia 1 60-min I Reperfusion I Reperfusion ( Reperfusion 
Vardenafil24 hrs (Group I) 
RPP 1 10482 f 1762" 1 9671 + 1 128 1 6545 f 495a3e 1 6669 f 469".' 1 5918 f 526",",' ( 5208 f 736ae.f 
Vardenafil24 hrs + L-NAME (Group 111) 
HR 
MAP 
RPP 
Saline Control 24 hrs (Group 11) 
HR 
MAP 
MAP 
RPP 
143 f 10' 
64 f 3e-f 
10575 f 732e-f 
182 f 13 
80 f 3' 
HR 
Vardenafil7 days (Group IV) 
182f 15 
84 f 3 
17709f2217 
187f 9 
1 0 0 f 7  
193f 8 180f 17 
8 3 f  8 
188 1 1 + 32 1 8b.d 
MAP 
RPP 
126f 12e-f 
67 f 5e.f 
9 1 10 f 976e,f 
168+ 13 
75 + 3e,f 
HR 
Saline Control 7 days (Group V) 
190f 14 
8 0 f  2 
17248f1708 
135 f 13".~ 
6 1 f se.' 
9639 f 1 003~,' 
164f 15 
70 f 6".' 
1495 18 
107f 10 
2394 1 f 3 1 37ab.c.d 
197f 8 
7 5 f 5  
17180 f 1044 
MAP 
RPP 
169f 6 
66 f 3e.f 
12937 f 887 
198 f 15 
HR 
Vardenafil7 days + L-NAME (Group VI) 
RPP I 17837 f 9 2 0 ~ ~ ~  1 17426 f 805"~ 1 14346 f 1 0 3 5 ~ ~ ~  ( 12609 f I I 84bdef 1 12286 f 1397b-d3e*f 1 10761 f 999b-dse.f 
Values are means 7t SEM. HR - Heart rate (beats/min); MAP - Mean arterial blood pressure (mmHg); RPP - Rate pressure product (mmHg/min). 
145 + 18 
86 f 8".' 
14 105 f 1 1 84b.d.f 
201 f 14 148 f I 145 f 8e,f 
7 4 f 5  
17265 f 1038~  
201 f 7 199f 13 
9 4 f 5  
9458 f 922" 
MAP 
RPP 
L-NAME Control (Group VII) 
HR 
MAP 
'P<O.05 vs Var24hrs, b ~ < ~ . 0 5  vs saline 24hrs, 'P<O.05 vs Var 7 days, d ~ < ~ . 0 5  vs saline 7days, eP<0.05 vs baseline, f ~ < ~ . 0 5  vspre-ischemia. 
1912 14 
9 6 f  6 
141 f 6e,f 
171 f 11 1 13 1 f 1 3C-e-f 1 12 1 f 9b.d3e3f I 1 17 f I O ~ - ~ - '  . I 1 1 l f 1 2b,d,e.f HR 
177f 12 
79 + 3e 
145 f lod 
6 6 f  10' 
10263 f 663',' 
65 f 3  
15905 f 1132~  
196f 7 
9 3 f 4  
9054 f 687' 
1 8 9 f 8  
87 + 13 
19593 f 1488~~ '  
182f 8 
8 5 f  6 
134f l l d  
52 f 8b.f 
8674 f 852".' 
6 9 f  4 
12044 + 8 ~ 8 ~ ~ ~ ~ '  
193 f 6esf 
8 2 f  4 
6959 f 709".' 
104f 7 
1971 2 f 1 1 Bb,' 
191 f 9 
101 f 23 
55 f 10' 
83 1 1 f 1 054".~ 
1 96 f 6a'-esf 1 1 96 + 7ac.e-f 
6 9 + 2  
11513 f 647b,e,f 
7 3 f 3  
5579 f 5 1 6a-',e.f 
8 2 f 6  
1 1805 f 993'3e9f 
177 f 13 
75 f 3 
6 6 f  3 
10773 f 807b-esf 
6 9 f  4 
5037 f 6 1 9a.c-e-f 
82 f 1 
1 1200 f 908b-d.e,f 
160f 19 
7 0 f  1 
64 f 4 
4365 f 542a.c,e,f 
74 f 5 
9792 f 656b.d.e3f 
155 f 20 
6 9 f  1 
7 2 f  7 
8748 f 3 1 9b.d-e-f 
138 + lsd 
6 8 f 1  
DISCUSSION 
Ischemic heart disease, as the underlying cause of most cases of acute myocardial 
infarction (AMI), congestive heart failure, arrhythmias, and sudden cardiac death, is the 
leading cause of morbidity and mortality in all industrialized nations. In the United States, 
ischemic heart disease causes nearly 20% of all deaths (approximately 600,000 deaths each 
year), with greater than half of these deaths occurring before the patient arrives at the 
hospital, primarily due to arrhythmias and cardiac arrest. An estimated 1.1 million 
Americans will have a new or recurrent AM1 this year, and many survivors will experience 
lasting morbidity, with progression to heart failure and death. As the population grows 
older and co-morbidities such as obesity and diabetes become more prevalent, the 
enormous public health burden caused by ischemic heart disease is likely to increase even 
more. Two critical factors are required in order to improve the outcome of a patient 
suffering fiom an acute, ischemic event. First, the patient must survive any arrhythmias. 
The majority of deaths due to AM1 occur prior to hospitalization, due primarily to 
arrhythmias and cardiac arrest. Although greater access to automatic defibrillators and 
optimization of CPR protocols offer tremendous potential to save lives, it is remarkable 
that survival is still dependent upon early CPR and rapid defibrillation. Indeed, survival 
rates fiom cardiac arrest have shown only marginal improvements over the last 30 years, 
which further underscores the need for novel therapies and resuscitation strategies. 
Second, infarct size needs to be limited. For patients with AM1 who do not succumb to 
out-of-hospital arrhythmias and are successfully transported to the hospital, the prognosis 
is dependent on the amount of myocardium that is lost as a result of ischemia/reperfusion 
injury. There is no question that timely reperfusion (by thrombolysis or percutaneous 
transluminal coronary angioplasty [PTCA]) can salvage ischemic myocardium - and has, 
indeed, become the standard in-hospital treatment for AMI. Although greater benefits can 
conceptually be achieved by continued efforts to implement even earlier restoration of 
coronary flow, delays in seeking medical attention, together with inherent logistic and 
temporal limitations in initiating thrombolysis or PTCA, make it unlikely that additional 
and substantive improvements in morbidity and mortality can be achieved by reperfusion 
therapy alone. 
Limitation of myocardial ischemidreperfusion injury is also of paramount 
importance in the setting of global myocardial ischemia associated with coronary artery 
bypass graft (CABG) surgery. Despite the considerable progress that has been made to 
date, high-risk subsets of patients (i.e., repeat CABG, unstable angina, LV dysfunction, 
diabetes, old age, etc.) continue to exhibit post-operative complications, including 
prolonged contractile dysfunction (stunning), low-output syndrome, peri-operative 
myocardial infarction, and cardiac failure requiring prolonged intensive care. Thus, both 
in patients experiencing an AM1 and in those undergoing CABG surgery, there is a 
compelling, but still unfulfilled, need to protect the ischemic myocardium. 
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In recent studies from Dr. Kukreja's laboratory, it was shown that PDE-5 inhibitors 
sildenafil (viagraB) and vardenafil ( ~ e v i t r a ~ )  induce preconditioning-like protective 
effects against ischemia-reperfusion injury in adult rabbit hearts. Sildenafil administered 
30 minutes (acutely) or 24 hours (delayed) prior to ischemia-reperfusion has previously 
been shown to be an effective means for cardioprotection in the rabbit heart (28). 
However, the efficacy of these drugs in causing long-term protection following 
ischemidreperfusion injury has not been investigated. In this study, we wanted to test if 
sildenafil could outlast the second window of protection seen in classical ischemic 
preconditioning. Therefore, along with 24-hour delayed protection studies with sildenafil, 
we administered sildenafil 48 hrs, 96 hrs, and 7 days prior to undergoing the ischemia- 
reperfusion protocol. We found significant protection at all time points. At 48 hrs, we 
observed reduction in infarct size from 34.38% % 1.46 in saline controls to 15.15% 2.01 
with sildenafil treatment. On day 7 after administration of sildenafil, the infarct size was 
reduced to 16.37% * 1.94 as compared 37.28% % 1.39 in saline control (p < 0.05). 
Furthermore, we observed a similar reduction in infarct size with vardenafil when 
administered 24 hrs or 7 days prior to ischemidreperfusion. This confirms our hypothesis 
that PDE-5 inhibitors have a "class effect" in terms of long-term cardioprotection. 
Transient decreases in systemic pressures have been reported as acute responses to 
both drugs. For example, Ockaili et a1 (28) reported that intravenous administration of 
sildenafil caused a rapid decrease in hemodynamics as indicated by the 24.5%, 47.3% and 
38.8% decline in systolic, diastolic, and mean arterial pressures, respectively, within 2 min 
of receiving the drug. The systemic hemodynamics returned to nearly baseline levels 
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5 min after treatment with sildenafil. The effect of orally administered sildenafil citrate on 
systemic hemodynamics was milder and slower compared with the intravenous dose of the 
drug. The orally administered sildenafil caused a 9.2%, 12.5%, and 10.3% decrease in 
systolic, diastolic, and mean arterial pressure, respectively, ,after 30 min of treatment with 
the drug. This hypotensive response remained significantly depressed even at 60 min after 
oral administration of the drug. No changes in heart rate were observed. However, we did 
not see any changes in baseline hemodynamics 24-168 hours after drug administration. 
Although L-NAME abolished cardioprotection at all time intervals, suggesting that there 
must be some up-regulation of iNOS andlor eNOS protein levels following treatment with 
these drugs, this increase may not be enough to elicit a systemic hypotensive response. 
Chen et al suggested that hypovolemic hypotension has a preconditioning effect in the 
rabbit heart. They found that hypovolemic hypotension preconditioning significantly 
improves cardiopulmonary function and increases NO formation and that the protective 
benefit associated with hypovolemic hypotension preconditioning of the heart may be 
regulated through NO mediated mechanism (6). Therefore, hypotensive preconditioning 
could be one of the mechanisms producing a PC-like effect in our long-term studies. 
The exact mechanism of long-term protection by PDE-5 inhibition is not filly 
understood. However our data suggest that NO generated after treatment with sildenafil or 
vardenafil plays an essential role in long-term protection. Treatment with a non-selective 
blocker of nitric oxide synthases (L-NAME) abolished the protection conferred by 
sildenafil as well as vardenafil. The infarct size was increased to the size similar to saline 
controls (Figures 5 and 7). NO has been shown to play a prominent role both in initiating 
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and in mediating the cardioprotective response of preconditioning. Several studies from 
our laboratory have demonstrated that delayed pharmacological PC is mediated by the 
upregulation of iNOS in the myocardium (40, 46, and 47). Bolli and colleagues have 
shown that NO is the key trigger as well as a key media$or of PC in rabbit and mouse 
hearts (4, 16). In the Langendorff isolated perfused mouse heart model subjected to 20 
minutes of global ischemia and 30 minutes of reperfusion, pre-treatment of the animals 
with sildenafil reduced myocardial infarct size 24 hours later compared with saline controls 
(32). 
Sildenafil-induced protection was abolished by a selective iNOS inhibitor, 1400W. In 
these studies, sildenafil did not alter pre-ischemic or post-ischemic coronary flow, 
indicating that its cardioprotective effect may be independent of its vascular response 24 
hours later. RTPCR showed a transient increase in the levels of both eNOS and iNOS, 
peaking at 45 minutes (eNOS) and 2 hours (iNOS) after sildenafil treatment and returning 
to baseline levels several hours later. The magnitude of increase was much higher for 
iNOS mRNA as compared with eNOS mRNA. In addition, cardiac expression of iNOS 
and eNOS protein was significantly elevated 24 hours after sildenafil treatment. These 
studies suggest that sildenafil induces delayed preconditioning 24 hrs later and that this 
response is primarily mediated by NO derived from iNOS. Similarly in isolated 
cardiomyocytes (1 I), sildenafil caused a significant increase in mRNA and protein 
expression of iNOS and eNOS (to a lesser extent). Also, sildenafil-induced protection 
against necrosis and apoptosis was abolished in myocytes deprived of iNOS, but not in 
eNOS gene knockout mice. Interestingly, sildenafil-treated myocytes demonstrated an 
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early increase in the Bcl-21Bax ratio following simulated ischemia-reperfusion, which may 
have been responsible for the anti-apoptotic effect of sildenafil. The increase of the Bcl- 
21Bax ratio, as well as the anti-apoptotic effects of sildenafil, were inhibited by treatment 
with the NOS inhibitor, L-NAME, thus suggesting the role of NO signaling in the 
protective effect of the drug against apoptosis. In the present study, the role of NO derived 
from nitric oxide synthase is clearly indicated by the ability of L-NAME to block the 
protection; however, we have not identified the specific isoform of the enzyme. As 
mentioned above, although iNOS is involved in cardioprotection 24 hrs later with 
sildenafil, we do not know whether the same isoform of the enzyme is implicated in long 
term protection observed at 48-168 hrs following treatment with sildenafil or vardenafil. 
Wang et a1 suggested that cardioprotection at 72 hrs after the initial bouts of ischemic 
preconditioning was mediated by nNOS and cyclooxygenase-2 (42). Surprisingly, the 
iNOS expression was not increased at 72 hours; however, upregulation of nNOS was 
evident at both the mRNA as well as protein levels. These changes were accompanied by 
an increase in myocardial nitritehitrate. Furthermore, the nNOS-selective inhibitors N- 
propyl-1-arginine or S-ethyl N-[4-(trifluoromethyl)phenyl] isothiourea completely blocked 
the protection of delayed preconditioning at 72 hours, whereas the iNOS-selective inhibitor 
S-methylisothiourea had no effect (33). It is possible that a similar shift in the source of 
NO occurs following long-term protection with PDE-5 inhibitors. Future studies will 
address this important issue. 
There are several possibilities by which NO may induce a cardioprotective effect. 
Enhanced synthesis of cGMP has been shown to be a requirement for the protection in 
delayed-ischemic PC in the rabbit hearts (19). In these studies, the role of cGMP did not 
exist during the early (acute) phase of ischemic PC. It was proposed .that NO participates 
in PC via two distinct mechanisms; it triggered delayed ischemic PC on acutely via a 
cGMP-independent mechanism and yet it mediated delayed PC 24 hrs later via a cGMP- 
dependent mechanism. Furthermore, cGMP may activate PKG (protein kinase G), which 
can subsequently open mitochondrial KATP channels (17). Conceptually, sildenafil plays a 
pivotal role in cardioprotection because it inhibits the enzymatic hydrolysis of cGMP and 
maintains the tissue accumulation of cGMP, thus leading to the downstream protective 
mechanism that involves the PKG-activated mitochondrial-KA~p channel. In addition, it 
was proven that myocardial cGMP content was in fact enhanced following the 
pretreatment rats with the cardioprotective dose of sildenafil (1 1). Further studies that 
would prove helpfd in this area would be to examine tissue levels of cGMP and NO at the 
appropriate time intervals. Quantifying those concentrations in the tissues would allow us 
to determine the thresholds these biochemical mediators must reach in order to achieve a 
cardioprotective effect with PDE-5 inhibitors in the heart. 
The opening of mitochondrial KATP channels may be one of the important mechanisms 
of long-term cardioprotection achieved with PDE-5 inhibitors. Several studies have now 
conclusively demonstrated that opening mitoKATP channels plays an important role in 
ischemic as well as pharmacological preconditioning in the heart. In the rabbit studies, 
Ockaili et a1 found that both acute and delayed cardioprotective effects were blocked by 5- 
HD, suggesting that opening of mitochondrial KATP channels does in fact play an important 
role in the infarct size reduction by sildenafil (28). Mitochondria are known to play an 
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essential role in cell survival by ATP synthesis and maintenance of ca2' homeostasis. 
Opening of the mitoKATP channel partially compensates the membrane potential, which 
allows for additional protons to be pumped out, forming an H' electrochemical gradient for 
both ATP synthesis and ca2' transport (39, 15). The delayed PC could be through the 
signaling cascade leading to the synthesis of iNOS, generation of NO and opening of the 
mitoKATP channels as described previously (27,33, and 43). 
In summary, we have shown that a novel class of PDE-5 inhibitors, including 
sildenafil and vardenafil, can reduce myocardial infarct size following 
ischemia/reperfusion up to 7 days following treatment. Our results also suggest that such a 
long lasting protective effect of these drugs is mediated by NO generated from nitric oxide 
synthase. These studies could be important in terms of harvesting the clinical potential of 
phosphodiesterase-5 inhibitors for protection of the heart against ischemiaheperfusion 
injury in patients with coronary artery disease. 
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